GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Poniard Pharmaecuticals, Inc. (PARD) [hlAlert]

Rating:
Outperform
PARD
down 99.95 %

Poniard Pharmaecuticals, Inc. (PARD) rated Outperform by BMO Capital Markets

Posted on: Tuesday,  Oct 6, 2009  8:25 AM ET by BMO Capital Markets

BMO Capital Markets rated Outperform Poniard Pharmaecuticals, Inc. (OTCBB: PARD) on 10/06/2009, when the stock price was $287.60.
Since then, Poniard Pharmaecuticals, Inc. has lost 99.96% as of 08/27/2015's recent price of $0.12.
If you would have followed this BMO Capital Markets's recommendation on PARD, you would have lost 99.95% of your investment in 2151 days.

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of cancer therapy products. Its lead product candidate is picoplatin, a platinum-based cancer therapy. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance in the treatment of solid tumors. The Company initiated a Phase III SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in small cell lung cancer. The Company is also conducting separate Phase I/II studies of picoplatin in the treatment of patients with metastatic colorectal cancer and hormone-refractory prostate cancer. NeoRx Manufacturing Group, Inc. is a wholly owned subsidiary of the Company.

The U.S. Equity Research team comprises over 25 analysts located in New York, Atlanta, Boston, Denver, Houston and Los Angeles. We cover more than 375 stocks and also provide equity strategy, quantitative analysis and portfolio management services to our clients. Our goal is to identify the best sectors to invest in, and the best stocks within those sectors, in order to help our clients maximize their portfolio returns. Our award-winning analysts provide research that is informative, perceptive and actionable.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/6/2009 8:25 AM Buy
None
287.60
as of 12/31/2009
1 Week down  -63.21 %
1 Month down  -69.66 %
3 Months down  -91.09 %
1 YTD down  -91.09 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy